Tigecycline is regarded as a last-resort treatment for multidrug-resistant Acinetobacter baumannii. However, tigecycline resistance in A. baumannii has increased worldwide. In this study, we investigated heteroresistance isolates from South Korea. Antibiotic susceptibility testing was performed on 323 nonduplicated isolates. Among 260 and 37 tigecycline-susceptible -intermediate-resistant isola...

BACKGROUND Acinetobacter baumannii has emerged as a highly troublesome pathogen and a leading cause of mortality and morbidity among hospitalized burn patients. OBJECTIVES The aims of this study were to determine the frequency of the AdeABC genes and the role of the efflux pump (s) in the imipenem resistance of A. baumannii strains isolated from burn patients. MATERIALS AND METHODS This stu...

conclusions adeabc efflux system plays a vital role in multidrug resistance in clinical a. baumannii isolates. it was noted that the most important gene responsible for multidrug resistance within this system was the adeb gene especially in carbapenems resistance. methods this study was conducted on 84 multidrug resistant and 13 carbapenem-susceptible a. baumannii isolates obtained from burn an...

conclusions the efflux pump may play a role in antibiotic resistance in a. baumannii isolates. the ability of a. baumannii isolates to acquire drug resistance by the efflux pump mechanism is a concern. thus, new strategies are required in order to eliminate the efflux transport activity from resistant a. baumannii isolates causing nosocomial infections. background acinetobacter baumannii has em...

Sir, Tigecycline is a therapeutic option for multidrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae infections. Recently, tigecycline-non-susceptible A. baumannii and K. pneumoniae have been reported in patients receiving tigecycline. Despite several reports concerning in vitro and in vivo susceptibility of bacterial pathogens to tigecycline, there is a paucity of data regarding ...